Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma

British Journal of Haematology

Volumn 160, Issue 2, 2013, Pages 207-215

  Corazzelli, Gaetano ^a   Angrilli, Francesco ^b   D'Arco, Alfonso ^c   Ferrara, Felicetto ^d   Musto, Pellegrino ^e   Guarini, Attilio ^f   Cox, Maria Christina ^g   Stelitano, Caterina ^h   Storti, Sergio ⁱ   Iannitto, Emilio ^j   Falorio, Simona ^b   Califano, Catello ^c   Amore, Alfonso ^a   Arcamone, Manuela ^a   De Filippi, Rosaria ^a,k   Pinto, Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SPIRITO SANTO HOSPITAL   (Italy)

^c 'Umberto I' Hospital   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^f NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j Ospedale SS Annunziata   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

Alkylating agents; Bendamustine; Hodgkin lymphoma; Salvage chemotherapy; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; MEPREDNISONE; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BLOODSTREAM INFECTION; CANCER RADIOTHERAPY; CATHETER INFECTION; CELLULITIS; CLINICAL ARTICLE; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; LUNG INFECTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RECURRENT CANCER; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE CHECKPOINTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA REPAIR; DRUG EVALUATION; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; OFF-LABEL USE; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872275912     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12120     Document Type: Article

References (38)

1. Aldinucci, D., Gloghini, A., Pinto, A., De Filippi, R. & Carbone, A. (2010) The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. Journal of Pathology, 221, 248-263.
2. Apostolopoulos, C., Castellano, L., Stebbing, J. & Giamas, G. (2008) Bendamustine as a model for the activity of alkylating agents. Future Oncology, 4, 323-332.
3. Bauer, K., Skoetz, N., Monsef, I., Engert, A. & Brillant, C. (2011) Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. The Cochrane Database of Systematic Reviews, CD007941.
4. Brice, P. (2008) Managing relapsed and refractory Hodgkin lymphoma. British Journal of Haematology, 141, 3-13.
5. Buglio, D., Georgakis, G. & Younes, A. (2007) Novel small-molecule therapy of Hodgkin lymphoma. Expert Review of Anticancer Therapy, 7, 735-740.
6. Byrne, B.J. & Gockerman, J.P. (2007) Salvage therapy in Hodgkin's lymphoma. Oncologist, 12, 156-167.
7. Canellos, G. & Josting, A. (2007) Management of recurrent Hodgkin Lymphoma. In: Hodgkin Lymphoma (ed. by R. Hoppe, P. Mauch, J. Armitage, V. Dielh & L. Weiss ), pp. 271-280. Lippincott Williams & Wilkins, Philadelphia, PA.
8. Cheson, B.D. (2007) The International harmonization project for response criteria in lymphoma clinical trials. Hematology/Oncology Clinics of North America, 21, 841-854.
9. Cheson, B.D. & Rummel, M.J. (2009) Bendamustine: rebirth of an old drug. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 1492-1501.
10. Cheson, B.D., Wendtner, C.M., Pieper, A., Dreyling, M., Friedberg, J., Hoelzer, D., Moreau, P., Gribben, J., Knop, S., Montillo, M. & Rummel, M. (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clinical Lymphoma, Myeloma & Leukemia, 10, 21-27.
11. Connors, J.M. (2005) State-of-the-art therapeutics: Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 6400-6408.
12. D'Elia, G.M., De Angelis, F., Breccia, M., Annechini, G., Panfilio, S., Danieli, R., Cavalieri, E. & Pulsoni, A. (2010) Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma. Leukemia Research, 34, e300-e301.
13. Eichbaum, M., Bischofs, E., Nehls, K., Schneeweiss, A. & Sohn, C. (2009) Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine. Drugs of Today, 45, 431-444.
14. Gandhi, V. & Burger, J.A. (2009) Bendamustine in B-cell malignancies: the new 46-year-old kid on the block. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 15, 7456-7461.
15. Garcia, J.F., Camacho, F.I., Morente, M., Fraga, M., Montalban, C., Alvaro, T., Bellas, C., Castano, A., Diez, A., Flores, T., Martin, C., Martinez, M.A., Mazorra, F., Menarguez, J., Mestre, M.J., Mollejo, M., Saez, A.I., Sanchez, L., Piris, M.A. & Spanish Hodgkin Lymphoma Study, G. (2003) Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood, 101, 681-689.
16. Holmberg, L. & Maloney, D.G. (2011) The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network, 9, 1060-1071.
17. Horning, S.J., Fanale, S., de Vos, S., Borchmann, P., Illidge, T., Engert, A., Arai, S. & Younes, A. (2008) Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [Abstract]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 19(Suppl. 4), iv120-iv121.
18. Hryniuk, W. (1998) The importance of dose intensity in outcome of chemotherapy. In: Important Advances in Oncology (ed. by S. Hellman, V. DeVita & S. Rosenberg ), pp. 121-141. Lippincott, Philadelphia, PA.
19. Jona, A. & Younes, A. (2010) Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Reviews, 24, 233-238.
20. Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R.J., Weber, W.A., Reske, S.N., Schwaiger, M., Schwartz, L.H., Zijlstra, J.M., Siegel, B.A. & Cheson, B.D. (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25, 571-578.
21. Kahl, B.S., Bartlett, N.L., Leonard, J.P., Chen, L., Ganjoo, K., Williams, M.E., Czuczman, M.S., Robinson, K.S., Joyce, R., van der Jagt, R.H. & Cheson, B.D. (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer, 116, 106-114.
22. Kuruvilla, J., Keating, A. & Crump, M. (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood, 117, 4208-4217.
23. Leoni, L.M. & Hartley, J.A. (2011) Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Seminars in Hematology, 48(Suppl. 1), S12-S23.
24. Leoni, L.M., Bailey, B., Reifert, J., Bendall, H.H., Zeller, R.W., Corbeil, J., Elliott, G. & Niemeyer, C.C. (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 14, 309-317.
25. Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., McMillan, A., Chopra, R., Milligan, D. & Hudson, G.V. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet, 341, 1051-1054.
26. Magyari, F., Simon, Z., Barna, S., Udvardy, M., Varoczy, L. & Illes, A. (2011) Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation. Hematological Oncology, 30, 98-100.
27. Moskowitz, A.J., Hamlin, P., Gerecitano, J., Horwitz, S., Matasar, M., Noy, A., Palomba, M. L., Portlock, C., Straus, D., Graustein, T., Zelenetz, A. & Moskowitz, C. (2011) Updated results of a phase II trial of bendamustine in relapsed and refractory Hodgkin lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 22(Suppl. 4), iv180-iv181.
28. Roue, G., Lopez-Guerra, M., Milpied, P., Perez-Galan, P., Villamor, N., Montserrat, E., Campo, E. & Colomer, D. (2008) Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 14, 6907-6915.
29. Steidl, C., Connors, J.M. & Gascoyne, R.D. (2011) Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. Journal of Clinical Oncology, 29, 1812-1826.
30. Strumberg, D., Harstrick, A., Doll, K., Hoffmann, B. & Seeber, S. (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti-Cancer Drugs, 7, 415-421.
31. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC, Lyon, France.
32. Tageja, N. & Nagi, J. (2010) Bendamustine: something old, something new. Cancer Chemotherapy and Pharmacology, 66, 413-423.
33. Uhm, J. & Kuruvilla, J. (2012) Treatment of newly diagnosed advanced stage Hodgkin lymphoma. Blood Review, 26, 167-174.
34. Ujjani, C. & Cheson, B.D. (2010) Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Expert Review of Anticancer Therapy, 10, 1353-1365.
35. Visani, G., Malerba, L., Stefani, P.M., Capria, S., Galieni, P., Gaudio, F., Specchia, G., Meloni, G., Gherlinzoni, F., Giardini, C., Falcioni, S., Cuberli, F., Gobbi, M., Sarina, B., Santoro, A., Ferrara, F., Rocchi, M., Ocio, E.M., Caballero, M.D. & Isidori, A. (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood, 118, 3419-3425.
36. Younes, A. (2009) Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology/The Education Program of the American Society of Hematology, 1, 507-519.
37. Younes, A., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., Ramchandren, R., Bartlett, N.L., Cheson, B.D., de Vos, S., Forero-Torres, A., Moskowitz, C.H., Connors, J.M., Engert, A., Larsen, E.K., Kennedy, D.A., Sievers, E.L. & Chen, R. (2012a) Results of a pivotal phase II study of brentuximab vedotin for patients With relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 2183-2189.
38. Younes, A., Yasothan, U. & Kirkpatrick, P. (2012b) Brentuximab vedotin. Nature Reviews. Drug Discovery, 11, 19-20.